Bringing New Blood to the Anemia Market
This article was originally published in Start Up
Executive Summary
Sales of erythropoiesis-stimulating agents for treating anemia totaled approximately $11.5 billion in 2008, about $7 billion in the US. Any emerging venture expecting to sink its teeth into this huge market will need to prove its future product offers greater ease of manufacture, storage, and administration, and lower price and a better safety profile compared with the widely used biologics, while overcoming the higher barriers to approval set by the FDA.
You may also be interested in...
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Start-Up Previews (12/2009)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Bringing New Blood to the Anemia Market," features profiles of Akebia, Neumedicines and Palkion. Plus these Start-Ups Across Health Care: Aterovax, Pico-Tesla Magnetic Therapies, SpineAlign Medical, Theraclion, Virdante Pharmaceuticals and Zacharon Pharmaceuticals.